TRAIL Monoclonal antibody

TRAIL Monoclonal Antibody for IHC, WB, ELISA

Host / Isotype

Mouse / IgG1

Reactivity

Human and More (1)

Applications

WB, IHC, IF, ELISA

Conjugate

Unconjugated

CloneNo.

1B9B4

Cat no : 66756-1-Ig

Synonyms

Apo 2 ligand, Apo 2L, APO2L, CD253, Protein TRAIL, TL2, TNFSF10, TRAIL



Tested Applications

Positive WB detected inhuman milk tissue
Positive IHC detected inhuman tonsillitis tissue, human prostate cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:2000
Immunohistochemistry (IHC)IHC : 1:50-1:500
Sample-dependent, check data in validation data gallery

Product Information

66756-1-Ig targets TRAIL in WB, IHC, IF, ELISA applications and shows reactivity with Human samples.

Tested Reactivity Human
Cited Reactivityhuman
Host / Isotype Mouse / IgG1
Class Monoclonal
Type Antibody
Immunogen TRAIL fusion protein Ag25746
Full Name tumor necrosis factor (ligand) superfamily, member 10
Calculated molecular weight 281 aa, 33 kDa
Observed molecular weight 28-30 kDa
GenBank accession numberBC032722
Gene symbol TNFSF10
Gene ID (NCBI) 8743
Conjugate Unconjugated
Form Liquid
Purification Method Protein A purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

TNFSF10/TRAIL (tumor necrosis factor superfamily member 10) is a typical death ligand expressed on natural killer cells and cytotoxic T lymphocytes. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. TNFSF10 induces apoptotic cell death in cancer by binding to its functional death receptors, death receptor (DR) 4 (TNFRSF10A/TRAIL-R1) and DR5 (TNFRSF10B/TRAIL-R2) to activate the extrinsic apoptosis pathway. TRAIL also activates c-Jun N-terminal kinase (MAPK8/JNK) and the transcription factor nuclear factor-κB (NFκB). The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3.

Protocols

Product Specific Protocols
WB protocol for TRAIL antibody 66756-1-IgDownload protocol
IHC protocol for TRAIL antibody 66756-1-IgDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

Cancers (Basel)

Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib.

Authors - Changhong Ke
human

Adv Healthc Mater

TRAIL-Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582).

Authors - Huan Hou
humanIF

Front Bioeng Biotechnol

The inhibitory effect of human umbilical cord mesenchymal stem cells expressing anti-HAAH scFv-sTRAIL fusion protein on glioma

Authors - Tian Xue